Abstract
Arterial hypertension heavily contributes to the global cardiovascular burden of morbidity and mortality, as well as to increase individual absolute cardiovascular risk. In addition, the clustering of cardiovascular risk factors and target organ damage in hypertensive patients is indeed an extremely frequent observation in both the epidemiological studies and in the clinical practice. In this view, a systematic research of intermediate endpoints or disease markers may represent an useful strategy in order to evaluate the presence of target organ damage as well as to predict cardiovascular events in essential hypertension. In fact, when considering the long natural history of hypertension, it appears very useful to postulate that modifications in measurable intermediate endpoints may permit a better evaluation of the efficacy of a given treatment in preventing or modifying the course of target organ damage, rather than variation in the future risk for development of hard endpoints. This represents a valuable approach in the clinical practice and can be easily undertaken by physicians to evaluate the status of a patient, the prognosis and the effectiveness of a treatment through a better stratification of absolute cardiovascular risk in individual patients, resulting in a more strict and cost-effective control of high blood pressure levels.
Keywords: Target Organ Damage, Left Ventricular Hypertrophy, Carotid Atherosclerosis, Intima-Media Thickness measurements, MICROALBUMINURIA
Current Hypertension Reviews
Title: Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension
Volume: 3 Issue: 3
Author(s): Massimo Volpe and Giuliano Tocci
Affiliation:
Keywords: Target Organ Damage, Left Ventricular Hypertrophy, Carotid Atherosclerosis, Intima-Media Thickness measurements, MICROALBUMINURIA
Abstract: Arterial hypertension heavily contributes to the global cardiovascular burden of morbidity and mortality, as well as to increase individual absolute cardiovascular risk. In addition, the clustering of cardiovascular risk factors and target organ damage in hypertensive patients is indeed an extremely frequent observation in both the epidemiological studies and in the clinical practice. In this view, a systematic research of intermediate endpoints or disease markers may represent an useful strategy in order to evaluate the presence of target organ damage as well as to predict cardiovascular events in essential hypertension. In fact, when considering the long natural history of hypertension, it appears very useful to postulate that modifications in measurable intermediate endpoints may permit a better evaluation of the efficacy of a given treatment in preventing or modifying the course of target organ damage, rather than variation in the future risk for development of hard endpoints. This represents a valuable approach in the clinical practice and can be easily undertaken by physicians to evaluate the status of a patient, the prognosis and the effectiveness of a treatment through a better stratification of absolute cardiovascular risk in individual patients, resulting in a more strict and cost-effective control of high blood pressure levels.
Export Options
About this article
Cite this article as:
Massimo Volpe and Giuliano Tocci , Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension, Current Hypertension Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157340207781386693
DOI https://dx.doi.org/10.2174/157340207781386693 |
Print ISSN 1573-4021 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6506 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential Role of Angiotensin Converting Enzyme and Vasopeptidase Inhibitors in the Treatment of Diabetic Neuropathy
Current Drug Targets The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Editorial (Thematic Issue: NADPH Oxidase-Derived ROS Signaling and Therapeutic Opportunities)
Current Pharmaceutical Design Update on Parenteral Nutrition-Associated Liver Disease: Pathogenesis and Management
Current Nutrition & Food Science Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Revised Roberts Cytoprotection and Adaptive Cytoprotection and Stable Gastric Pentadecapeptide BPC 157. Possible Significance and Implications for Novel Mediator
Current Pharmaceutical Design The Metabolic Syndrome and the Relevance of Nutrients for its Onset
Recent Patents on Biotechnology Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Current Medicinal Chemistry The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Comprehensive in silico Study of GLUT10: Prediction of Possible Substrate Binding Sites and Interacting Molecules
Current Pharmaceutical Biotechnology The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Pharmaceutical Design Vascular Remodelling in Well-controlled Hypertensive Patients: The Challenge of Residual Risk Management
Current Pharmaceutical Design Pharmacogenetic Aspects of Neuroleptic Malignant Syndrome
Current Pharmacogenomics Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies
Current Diabetes Reviews